1. NPSA rapid response report: safer administration of insulin, NPSA/2010/RR013; 2010. https://www.sps.nhs.uk/wp-content/uploads/2018/02/2010-NRLS-1243-Safer-administrnsulin-2010.06.16-v1.pdf [Accessed 20 Nov 2021].
2. ICS UK. Medication concentration in critical care areas; 2017. https://ics152.files.wordpress.com/2017/02/ics-standard-medication-concentrations-2016.pdf [Accessed 20 Nov 2021].
3. Huminsulin® Normal 100. Summary of product characteristics. Bad Homburg, Germany: Lilly Deutschland GmbH; 2020. https://www.fachinfo.de/pdf/007951?redirect-referrer=https%3A%2F%2Fwww.lilly-pharma.de%2Funsere-produkte%2Fproduktuebersicht [Accessed 22 Nov 2021].
4. Actrapid®
. Summary of product characteristics. Bagsvaerd, Denmark: Novo Nordisk A/S; 2019. https://www.ema.europa.eu/en/documents/product-information/actrapid-epar-product-information_de.pdf [Accessed 22 Nov 2021].
5. Insuman® Rapid 100 I.U./mL. Summary of product characteristics. Frankfurt, Germany: Sanofi-Aventis Deutschland GmbH; 2020. https://mein.sanofi.de/produkte/Insuman-Rapid/Downloads?id=d05502ab-3b87-4b28-8d43-a196c114243d [Accessed 22 Nov 2021].